middle.news
ImpediMed Expands US Reimbursement to 94% With New CEO Driving Growth
8:19am on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
ImpediMed Expands US Reimbursement to 94% With New CEO Driving Growth
8:19am on Thursday 30th of April, 2026 AEST
Key Points
Q3 FY26 revenue of $3.5 million, down 10% quarter-on-quarter
US reimbursement coverage expands to 94.3% of lives
Initial sales in Heart Health and Weight Management markets
Annual Recurring Revenue steady at $14.1 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Impedimed (ASX:IPD)
OPEN ARTICLE